Paper Details

  1. Home
  2. Paper Details

Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells.

Author: BieringScott B, ChienMinchen, Dugast-DarzacqClaire, GarziaAitor, GrahamThomas G W, JockuschSteffen, JuJingyue, MeyerCindy, NguyenlaXammy, NäärAnders M, PatelDinshaw J, RussoJames J, SchaletzkyJulia, StanleySarah, StroumzaJulien, TaoChuanjuan, TuschlThomas, Van DisErik, WangXuanting, WehriEddie, XieWei, YamashiroLivia H, ZhuChi

Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

HCV NS5A inhibitors, like velpatasvir and elbasvir, synergistically enhance the antiviral efficacy of remdesivir against SARS-CoV-2, providing a promising strategy for treating COVID-19.
Paper Details　
Original Abstract of the Article :
SARS coronavirus 2 (SARS-CoV-2) has caused an ongoing global pandemic with significant mortality and morbidity. At this time, the only FDA-approved therapeutic for COVID-19 is remdesivir, a broad-spectrum antiviral nucleoside analog. Efficacy is only moderate, and improved treatment strategies are u...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628577/

データ提供：米国国立医学図書館（NLM）

Combating COVID-19: Unveiling Synergistic Antiviral Combinations

The COVID-19 pandemic has posed a global health crisis, much like a desert storm that can overwhelm and disrupt the natural order. This study explores the potential of combining remdesivir, a current antiviral treatment for COVID-19, with other approved drugs to enhance its efficacy.

A Collaborative Approach to COVID-19 Treatment

Researchers identified 20 FDA-approved drugs that acted synergistically with remdesivir in preventing SARS-CoV-2 replication. Among these, Hepatitis C virus nonstructural protein 5A (HCV NS5A) inhibitors, velpatasvir and elbasvir, exhibited the strongest synergistic effects, potentially enhancing the potency of remdesivir by more than 25-fold.

A New Frontier in COVID-19 Therapeutics

This research offers exciting possibilities for developing more effective treatment strategies for COVID-19. The synergistic combination of remdesivir with approved drugs, particularly HCV NS5A inhibitors, could significantly improve patient outcomes and reduce the burden of the pandemic.

Dr.Camel's Conclusion

Like a caravan navigating a vast and unforgiving desert, our fight against COVID-19 requires collaboration and innovation. This research highlights the potential of synergistic combinations to overcome this challenging health crisis, offering hope for a brighter future.

Date :
  1. Date Completed 2022-11-04
  2. Date Revised 2023-09-18
Further Info :

Pubmed ID

36323770

DOI: Digital Object Identifier

PMC9628577

Related Literature

Article Analysis
・Effects of elbasvir and grazoprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.